Roland W. Herzog
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Roland W. Herzog has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Eric Dobrzynski
From the Department of Pediatrics, University of Pennsylvania Medical Center and Children's Hospital of Philadelphia, Philadelphia, PA
3 shared publicationsFederico Mingozzi
Department of Pediatrics and2 Department of Pathology, The Children’s Hospital of Philadelphia, and University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
2 shared publicationsKatherine A. High
Department of Pediatrics and2 Department of Pathology, The Children’s Hospital of Philadelphia, and University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
2 shared publicationsValder R. Arruda
Department of Pediatrics and2 Department of Pathology, The Children’s Hospital of Philadelphia, and University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
2 shared publicationsYi-Lin Liu
Department of Pediatrics and2 Department of Pathology, The Children’s Hospital of Philadelphia, and University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
2 shared publicationsAlexander Schlachterman
From the Department of Pediatrics, University of Pennsylvania Medical Center and Children's Hospital of Philadelphia, Philadelphia, PA
1 shared publication
Latest Publications
- 1 June 2005
- Published by American Society of Hematology in Blood
- Vol. 105 (11) , 4226-4234
Systemic protein delivery by muscle-gene transfer is limited by a local immune response
Adeno-associated viral (AAV) vectors have been successfully used for therapeutic expression of systemic transgene products (such as factor IX or erythropoietin) following in vivo administration to skeletal muscle of animal models of inherited hematologic disorders. However, an immune response may be initiated if the transgene product represents a neoantigen. Here, we use ovalbumin (OVA) as a model antigen and demonstrate immune-mediated elimination of expression on muscle-directed AAV-2 gene transfer. Administration to immune competent mice resulted in transient systemic OVA expression. Within 10 days, OVA-specific T-helper cells had been activated in draining lymph nodes, an inflammatory immune response ensued, and OVA-expressing muscle fibers were destroyed by a cytotoxic CD8+ T-cell response. Use of a muscle-specific promoter did not prevent this immune response. Adoptively transferred CD4+ cells transgenic for a T-cell receptor specific to OVA peptide-major histocompatibility complex class II showed antigen-specific, vector dose-dependent proliferation confined to the draining lymph nodes of AAV-OVA–transduced muscle within 5 days after gene transfer and subsequently participated in lymphocytic infiltration of transduced muscle. This study documents that a local immune response limits sustained expression of a secreted protein in muscle gene transfer, a finding that may have consequences for design of clinical protocols.
- 1 June 2005
- Published by American Society of Hematology in Blood
- Vol. 105 (11) , 4226-4234
Systemic protein delivery by muscle-gene transfer is limited by a local immune response
Adeno-associated viral (AAV) vectors have been successfully used for therapeutic expression of systemic transgene products (such as factor IX or erythropoietin) following in vivo administration to skeletal muscle of animal models of inherited hematologic disorders. However, an immune response may be initiated if the transgene product represents a neoantigen. Here, we use ovalbumin (OVA) as a model antigen and demonstrate immune-mediated elimination of expression on muscle-directed AAV-2 gene transfer. Administration to immune competent mice resulted in transient systemic OVA expression. Within 10 days, OVA-specific T-helper cells had been activated in draining lymph nodes, an inflammatory immune response ensued, and OVA-expressing muscle fibers were destroyed by a cytotoxic CD8+ T-cell response. Use of a muscle-specific promoter did not prevent this immune response. Adoptively transferred CD4+ cells transgenic for a T-cell receptor specific to OVA peptide-major histocompatibility complex class II showed antigen-specific, vector dose-dependent proliferation confined to the draining lymph nodes of AAV-OVA–transduced muscle within 5 days after gene transfer and subsequently participated in lymphocytic infiltration of transduced muscle. This study documents that a local immune response limits sustained expression of a secreted protein in muscle gene transfer, a finding that may have consequences for design of clinical protocols.
- 1 March 2005
- Vol. 8 (2) , 199-206
Recent advances in hepatic gene transfer: more efficacy and less immunogenicity.
Systemic enzyme deficiencies and lysosomal storage disorders are excellent targets for the treatment of genetic disease by in vivo gene transfer. To enable efficient delivery of therapeutic gene products into the systemic circulation, gene transfer to the liver has been extensively pursued. Hepatocytes are capable of overexpressing biologically active enzymes, such as coagulation factors (in the treatment of hemophilia) and lysosomal enzymes, and efficiently secrete these proteins into the blood stream. Sustained therapeutic expression and correction of rodent and canine animal models of human disease has been reported for a number of genetic disorders. This has been possible because of recent advances in vector development and optimization of their delivery. Viral vectors, in particular adeno-associated viral vectors and retroviral vectors, have yielded remarkable successes in the treatment of dogs with hemophilia or mucopolysaccharidosis. Such studies in large animals represent an important intermediate step toward clinical application, which has now been initiated in the case of hemophilia. Equally importantly, hepatic gene transfer has been demonstrated to induce immune tolerance to therapeutic transgene products.
- 1 March 2005
- Vol. 8 (2) , 199-206
Recent advances in hepatic gene transfer: more efficacy and less immunogenicity.
Systemic enzyme deficiencies and lysosomal storage disorders are excellent targets for the treatment of genetic disease by in vivo gene transfer. To enable efficient delivery of therapeutic gene products into the systemic circulation, gene transfer to the liver has been extensively pursued. Hepatocytes are capable of overexpressing biologically active enzymes, such as coagulation factors (in the treatment of hemophilia) and lysosomal enzymes, and efficiently secrete these proteins into the blood stream. Sustained therapeutic expression and correction of rodent and canine animal models of human disease has been reported for a number of genetic disorders. This has been possible because of recent advances in vector development and optimization of their delivery. Viral vectors, in particular adeno-associated viral vectors and retroviral vectors, have yielded remarkable successes in the treatment of dogs with hemophilia or mucopolysaccharidosis. Such studies in large animals represent an important intermediate step toward clinical application, which has now been initiated in the case of hemophilia. Equally importantly, hepatic gene transfer has been demonstrated to induce immune tolerance to therapeutic transgene products.
- 1 April 2004
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 30 (02) , 215-226
Immune Implications of Gene Therapy for Hemophilia
Similar to any novel treatment strategy for hemophilia, gene therapy faces the question of the risk of formation of inhibitory antibodies to the therapeutic factor VIII or factor IX protein. Activation of CD4+ or CD8+ T cells could lead to antibody formation or cytotoxic T lymphocyte responses to transgene-expressing cells. Preclinical studies in animal models of hemophilia A and B with different mutations in the dysfunctional gene shed light on the risk for such immune responses and point toward strategies to avoid immune activation or even promote tolerance induction. The impacts of variables such as choice and design of gene transfer vector, underlying gene mutation, route of vector administration, and transient immune suppression are discussed. Maintenance of immunological hyporesponsiveness to the therapeutic gene product is critical for successful gene therapy. Recent studies provide evidence for tolerance induction to coagulation factor antigens by viral hepatic or neonatal in vivo gene transfer, by in utero gene delivery, and by oral or nasal administration of protein or peptides.
- 1 April 2004
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 30 (02) , 215-226
Immune Implications of Gene Therapy for Hemophilia
Similar to any novel treatment strategy for hemophilia, gene therapy faces the question of the risk of formation of inhibitory antibodies to the therapeutic factor VIII or factor IX protein. Activation of CD4+ or CD8+ T cells could lead to antibody formation or cytotoxic T lymphocyte responses to transgene-expressing cells. Preclinical studies in animal models of hemophilia A and B with different mutations in the dysfunctional gene shed light on the risk for such immune responses and point toward strategies to avoid immune activation or even promote tolerance induction. The impacts of variables such as choice and design of gene transfer vector, underlying gene mutation, route of vector administration, and transient immune suppression are discussed. Maintenance of immunological hyporesponsiveness to the therapeutic gene product is critical for successful gene therapy. Recent studies provide evidence for tolerance induction to coagulation factor antigens by viral hepatic or neonatal in vivo gene transfer, by in utero gene delivery, and by oral or nasal administration of protein or peptides.
- 1 August 2003
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 1 (2) , 215-232
Update on gene therapy for hereditary hematological disorders
The past 3 years have been characterized by a number of impressive advances as well as setbacks in gene therapy for genetic disease. Children with X-linked severe combined immunodeficiency disorder (SCID-X1) have shown almost complete reconstitution of their immune system after receiving retrovirally transduced autologous CD34+ hematopoietic stem cells (HSCs). However, two of 11 treated patients subsequently developed a leukemia-like disease probablydue to the undesired activation of an oncogene. Gene transfer to HSCs resulted in substantial correction of immune function and multi-lineage engraftment in two patients with adenosine deaminase (ADA)-SCID. Several Phase I clinical trials for treatment of hemophilia A and B have been initiated or completed. Partial correction of hemophilia A, albeit transient, has been reported by ex vivo gene transfer to autologous fibroblasts. Intramuscular injection of adeno-associated viral (AAV) vector to patients with severe hemophilia B resulted in evidence of Factor IX gene transfer to skeletal muscle and a separate trial based on hepatic infusion of AAV vector is ongoing. Sustained therapeutic levels of coagulation factor expression have been achieved in preclinical models using retroviral, lentiviral, AAV and high capacity adenoviral vectors. Efficient lentiviral gene transfer to HSC in murine models of beta-thalassemia and sickle cell disease demonstrated sustained phenotypic correction.
- 1 August 2003
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 1 (2) , 215-232
Update on gene therapy for hereditary hematological disorders
The past 3 years have been characterized by a number of impressive advances as well as setbacks in gene therapy for genetic disease. Children with X-linked severe combined immunodeficiency disorder (SCID-X1) have shown almost complete reconstitution of their immune system after receiving retrovirally transduced autologous CD34+ hematopoietic stem cells (HSCs). However, two of 11 treated patients subsequently developed a leukemia-like disease probablydue to the undesired activation of an oncogene. Gene transfer to HSCs resulted in substantial correction of immune function and multi-lineage engraftment in two patients with adenosine deaminase (ADA)-SCID. Several Phase I clinical trials for treatment of hemophilia A and B have been initiated or completed. Partial correction of hemophilia A, albeit transient, has been reported by ex vivo gene transfer to autologous fibroblasts. Intramuscular injection of adeno-associated viral (AAV) vector to patients with severe hemophilia B resulted in evidence of Factor IX gene transfer to skeletal muscle and a separate trial based on hepatic infusion of AAV vector is ongoing. Sustained therapeutic levels of coagulation factor expression have been achieved in preclinical models using retroviral, lentiviral, AAV and high capacity adenoviral vectors. Efficient lentiviral gene transfer to HSC in murine models of beta-thalassemia and sickle cell disease demonstrated sustained phenotypic correction.
- 1 May 2003
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 111 (9) , 1347-1356
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Gene replacement therapy is an attractive approach for treatment of genetic disease, but may be complicated by the risk of a neutralizing immune response to the therapeutic gene product. There are examples of humoral and cellular immune responses against the transgene product as well as absence of such responses, depending on vector design and the underlying mutation in the dysfunctional gene. It has been unclear, however, whether transgene expression can induce tolerance to the therapeutic antigen. Here, we demonstrate induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver. Tolerized mice showed absence of anti-hF.IX and substantially reduced in vitro T cell responses after immunization with hF.IX in adjuvant. Tolerance induction was antigen specific, affected a broad range of Th cell subsets, and was favored by higher levels of transgene expression as determined by promoter strength, vector dose, and mouse strain. Hepatocyte-derived hF.IX expression induced regulatory CD4+ T cells that can suppress anti-hF.IX formation after adoptive transfer. With a strain-dependent rate of success, tolerance to murine F.IX was induced in mice with a large F.IX gene deletion, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
- 1 May 2003
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 111 (9) , 1347-1356
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer
Gene replacement therapy is an attractive approach for treatment of genetic disease, but may be complicated by the risk of a neutralizing immune response to the therapeutic gene product. There are examples of humoral and cellular immune responses against the transgene product as well as absence of such responses, depending on vector design and the underlying mutation in the dysfunctional gene. It has been unclear, however, whether transgene expression can induce tolerance to the therapeutic antigen. Here, we demonstrate induction of immune tolerance to a secreted human coagulation factor IX (hF.IX) antigen by adeno-associated viral gene transfer to the liver. Tolerized mice showed absence of anti-hF.IX and substantially reduced in vitro T cell responses after immunization with hF.IX in adjuvant. Tolerance induction was antigen specific, affected a broad range of Th cell subsets, and was favored by higher levels of transgene expression as determined by promoter strength, vector dose, and mouse strain. Hepatocyte-derived hF.IX expression induced regulatory CD4+ T cells that can suppress anti-hF.IX formation after adoptive transfer. With a strain-dependent rate of success, tolerance to murine F.IX was induced in mice with a large F.IX gene deletion, supporting the relevance of these data for treatment of hemophilia B and other genetic diseases.
- Open Access
- 1 January 2003
- Published by Taylor & Francis in BioTechniques
- Vol. 34 (1) , 184-189
Optimized Production of High-Titer Recombinant Adeno-Associated Virus in Roller Bottles
Adeno-associated viral (AAV) vectors are used for in vivo gene transfer in a number of preclinical models of genetic diseases (including large-animal models) and are currently being tested in clini...
- 1 January 2003
- Published by Taylor & Francis in BioTechniques
- Vol. 34 (1) , 184-189
Open AccessOptimized Production of High-Titer Recombinant Adeno-Associated Virus in Roller Bottles
Adeno-associated viral (AAV) vectors are used for in vivo gene transfer in a number of preclinical models of genetic diseases (including large-animal models) and are currently being tested in clini...
- Open Access
- 15 October 2002
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (20) , 10497-10502
Improved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector
Adeno-associated viral (AAV) vectors have been shown to direct stable gene transfer and expression in hepatocytes, which makes them attractive tools for treatment of inherited disorders such as hemophilia B. While substantial levels of coagulation factor IX (F.IX) have been achieved using AAV serotype 2 vectors, use of a serotype 5 vector further improves transduction efficiency and levels of F.IX transgene expression by 3- to 10-fold. In addition, the AAV-5 vector transduces a higher proportion of hepatocytes (∼15%). The subpopulations of hepatocytes transduced with either vector widely overlap, with the AAV-5 vector transducing additional hepatocytes and showing a wider area of transgene expression throughout the liver parenchyma.
- 15 October 2002
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (20) , 10497-10502
Open AccessImproved Hepatic Gene Transfer by Using an Adeno-Associated Virus Serotype 5 Vector
Adeno-associated viral (AAV) vectors have been shown to direct stable gene transfer and expression in hepatocytes, which makes them attractive tools for treatment of inherited disorders such as hemophilia B. While substantial levels of coagulation factor IX (F.IX) have been achieved using AAV serotype 2 vectors, use of a serotype 5 vector further improves transduction efficiency and levels of F.IX transgene expression by 3- to 10-fold. In addition, the AAV-5 vector transduces a higher proportion of hepatocytes (∼15%). The subpopulations of hepatocytes transduced with either vector widely overlap, with the AAV-5 vector transducing additional hepatocytes and showing a wider area of transgene expression throughout the liver parenchyma.
- 1 January 2001
- Published by Springer Nature in American Journal of PharmacoGenomics
- Vol. 1 (2) , 137-144
Gene Therapy for Hereditary Hematological Disorders
- 1 January 2001
- Published by Springer Nature in American Journal of PharmacoGenomics
- Vol. 1 (2) , 137-144
Gene Therapy for Hereditary Hematological Disorders